GoLiver Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A
  • (Upcoming)

  • Investors
  • 13

GoLiver Therapeutics General Information

Description

Developer of regenerative drugs intended to treat liver diseases without transplantation using differentiated pluripotent stem cells. The company engages in formulating regenerative drug candidates consisting of frozen allogeneic liver cells for the treatment of acute and chronic severe liver failure without the need for organ transplants, enabling businesses to use therapeutic options instead of transplants.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Quai Moncousu
  • BP 70721
  • 44000 Nantes
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 8 Quai Moncousu
  • BP 70721
  • 44000 Nantes
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GoLiver Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition Upcoming Generating Revenue
8. Later Stage VC 25-Sep-2024 Completed Generating Revenue
7. Grant 18-Mar-2021 Completed Generating Revenue
6. Grant 17-Jun-2020 Completed Generating Revenue
5. Seed Round 27-Aug-2019 Completed Generating Revenue
4. Corporate 30-Apr-2019 Completed Generating Revenue
3. Seed Round 11-Jun-2018 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Spin-Off 01-Apr-2017 Completed Generating Revenue
To view GoLiver Therapeutics’s complete valuation and funding history, request access »

GoLiver Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C shares
A Shares
C shares
C shares 14,356 $0.111001 $18.17 $18.17 1x $18.17 3.35%
C shares 66,098 $0.111001 $22.2 $22.2 1x $22.2 15.44%
To view GoLiver Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GoLiver Therapeutics Patents

GoLiver Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021233179-A1 Hepatic stem-like cells for the treatment and/or the prevention of fulminant liver disorders Pending 13-Mar-2020
CA-3170705-A1 Hepatic stem-like cells for the treatment and/or the prevention of fulminant liver disorders Pending 13-Mar-2020
EP-4118187-A1 Hepatic stem-like cells for the treatment and/or the prevention of fulminant liver disorders Pending 13-Mar-2020
WO-2021180984-A1 Hepatic stem-like cells for the treatment and/or the prevention of fulminant liver disorders Inactive 13-Mar-2020
US-20230407264-A1 Hepatic stem-like cells for the treatment and/or the prevention of liver disorders Inactive 13-Mar-2020 C12N5/0672
To view GoLiver Therapeutics’s complete patent history, request access »

GoLiver Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GoLiver Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Government of Francaise Government
Bpifrance Sovereign Wealth Fund
European Union Government
Developcentre Venture Capital Minority
SC Carat Patrimoine Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

GoLiver Therapeutics FAQs

  • When was GoLiver Therapeutics founded?

    GoLiver Therapeutics was founded in 2017.

  • Where is GoLiver Therapeutics headquartered?

    GoLiver Therapeutics is headquartered in Nantes, France.

  • What is the size of GoLiver Therapeutics?

    GoLiver Therapeutics has 10 total employees.

  • What industry is GoLiver Therapeutics in?

    GoLiver Therapeutics’s primary industry is Drug Discovery.

  • Is GoLiver Therapeutics a private or public company?

    GoLiver Therapeutics is a Private company.

  • What is GoLiver Therapeutics’s current revenue?

    The current revenue for GoLiver Therapeutics is .

  • How much funding has GoLiver Therapeutics raised over time?

    GoLiver Therapeutics has raised $4.01M.

  • Who are GoLiver Therapeutics’s investors?

    Government of Francaise, Bpifrance, European Union, Developcentre, and SC Carat Patrimoine are 5 of 13 investors who have invested in GoLiver Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process